Three Florida hospitals collaborate to advance personalized medicine
Three Florida healthcare institutions will collaborate to create Personalized Medicine Partnership of Florida (PMP Florida), which will conduct collaborative research on cancer and metabolic diseases.
Moffitt Cancer Center, Sanford-Burnham Medical Research Institute and Florida Hospital, as PMP Florida, will create partnerships among Florida-based centers of excellence in medical research and clinical care and work together to develop and utilize new molecular and genomic technologies to discover, translate and personalize interventions for preventing and treating debilitating diseases more efficiently to improve healthcare outcomes while reducing costs, according to a statement.
PMP Florida will leverage Moffitt's Total Cancer Care to develop similar research and clinical protocols in other disease areas including metabolic diseases. The partnership plans to hasten the discovery and development of new treatments by bringing together the complementary strengths of Florida Hospital's large patient population and clinical research expertise; Sanford-Burnham's fundamental research expertise and technology platforms; and Moffitt's biospecimen bank, data warehouse and personalized medicine capabilities.
Total Cancer Care is a treatment path that begins by mapping the more than 30,000 genes that make up a tumor to find its own unique genetic fingerprint. Through personalized medicine, Moffitt is working to create individualized therapies that are specific to each patient's type of cancer, and the way each person responds to the disease and treatment therapies.
Moffitt Cancer Center, Sanford-Burnham Medical Research Institute and Florida Hospital, as PMP Florida, will create partnerships among Florida-based centers of excellence in medical research and clinical care and work together to develop and utilize new molecular and genomic technologies to discover, translate and personalize interventions for preventing and treating debilitating diseases more efficiently to improve healthcare outcomes while reducing costs, according to a statement.
PMP Florida will leverage Moffitt's Total Cancer Care to develop similar research and clinical protocols in other disease areas including metabolic diseases. The partnership plans to hasten the discovery and development of new treatments by bringing together the complementary strengths of Florida Hospital's large patient population and clinical research expertise; Sanford-Burnham's fundamental research expertise and technology platforms; and Moffitt's biospecimen bank, data warehouse and personalized medicine capabilities.
Total Cancer Care is a treatment path that begins by mapping the more than 30,000 genes that make up a tumor to find its own unique genetic fingerprint. Through personalized medicine, Moffitt is working to create individualized therapies that are specific to each patient's type of cancer, and the way each person responds to the disease and treatment therapies.
Beth Walsh,
Editor
Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.